Clinical trials
Chronic Lymphocytic Leukemia clinical trials
Below are recruiting chronic lymphocytic leukemia clinical trials, each written for real people, not researchers. We’re tracking 203 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06821880Recruiting
Tracking infections and quality of life in blood cancer patients
This study uses a smartphone or web app to track infections and quality of life in people with multiple myeloma or chronic lymphocytic leukemia who have a weakened immune system. The goal is to create a better screening tool for infections and understand how the disease and treatment affect daily life.
Innsbruck, TyroliaAges 18 years+ - NCT07008885RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed/refractory B-ALL
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
Beijing, Biotherapeutic Department of Chinese PLA General HospitalAges 18–70 - NCT03219450RecruitingPhase 1
Personalized vaccine for early-stage, treatment-free CLL
This Phase 1 study tests a personalized cancer vaccine made from each patient’s CLL (“neoantigens”) plus a medicine called poly-ICLC to help the immune system learn to recognize the cancer. It is designed for people who have CLL but are currently not needing treatment, to see if it’s safe and may help keep the disease under control.
Boston, MassachusettsAges 18 years+ - NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Birmingham, AlabamaAges 18 years+ - NCT03801434RecruitingPhase 2
Ruxolitinib for people with certain eosinophil overgrowth diseases
This trial studies ruxolitinib to treat illnesses where the body makes too many eosinophils (a type of white blood cell) and symptoms or organ damage happen. It may help shrink disease activity when steroids are not enough, cannot be tolerated, or the illness comes back.
Palo Alto, CaliforniaAges 18 years+ - NCT05772273Recruiting
Test PD-1 drug plus azacitidine and donor cells for AML relapse
This study tests whether combining a PD-1 immune therapy, azacitidine, and low-dose donor lymphocyte infusion (donor immune cells) can treat AML that has come back after a stem cell transplant. It may help some people regain anti-cancer immune activity after relapse.
Suzhou, JiangsuAges Any age - NCT07677878RecruitingPhase 1
Blinatumomab and low-dose DLI after transplant for B-ALL
This trial tests adding a drug called blinatumomab plus a low-dose donor lymphocyte infusion (DLI) as maintenance therapy after stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL). It aims to reduce the chance of the cancer coming back.
BeijingAges 18–70 - NCT02203903RecruitingPhase 1
Donor T-cell treatment after transplant for high-risk AML and MDS
This Phase 1 trial studies an advanced form of donated immune cells given after a stem cell transplant to help prevent leukemia coming back. It mainly looks at safety and whether the treatment can work in people with very high-risk AML or MDS who have not relapsed.
Washington D.C., District of ColumbiaAges 6 months–80 years - NCT06643221RecruitingEarly Phase 1
Exercise as a booster for cell therapy treatments
This trial tests whether exercise and a heart medicine called isoproterenol can help your immune system work better with donor cell therapies. It may show how to make these treatments more effective.
Tucson, ArizonaAges 21–55 - NCT06765876RecruitingEarly Phase 1
CAR T-cell therapy for CD123+ blood cancers
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called CD123 on cancer cells. It is for people with certain blood cancers (AML, MDS-IB2, BPDCN, or ALL) that have come back or not responded to other treatments.
PragueAges 18–70 - NCT07105579RecruitingPhase 2
Blinatumomab and donor cells after transplant for high-risk B-ALL
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
HangzhouAges 14–65
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic lymphocytic leukemia?
- Yes. Clin2 currently lists 203 recruiting chronic lymphocytic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic lymphocytic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic lymphocytic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Acute Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Recurrent Chronic Lymphocytic Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Recurrent Transformed Chronic Lymphocytic Leukemia
- Refractory Transformed Chronic Lymphocytic Leukemia
- Acute Myeloid Leukemia
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.